Science Explorer Back to mapMap
Discussion
Company · Radnor · United States

Marinus Pharmaceuticals (United States)

marinuspharma.comROR OpenAlex
Research works
34
▲ 49% vs 2018-21
Citations
522
15.4 per fractional work
Top-10% rate
6.8%
all institutions 10.0%
Open access
33%
world 40%
International
25%
world 18%
Marinus Pharmaceuticals (United States)

Not ranked overall: Marinus Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Marinus Pharmaceuticals (United States) work in?

In all years, 44% of research at Marinus Pharmaceuticals (United States) is in Health Sciences, 29% in Life Sciences. Its largest fields are Medicine (43%), Neuroscience (10%), Engineering (9%). It does 1.6× the world's share of Health Sciences.

Health Sciences: 15 fractional works · 43.5% of its workMedicine: 15 fractional works · 43.2% of its workPsychiatry and Mental health: 3 fractional works · 9.3% of its workPulmonary and Respiratory Medicine: 2 fractional works · 7.1% of its workNeurology: 1 fractional works · 3.0% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 2.6% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 2.6% of its workGenetics: 1 fractional works · 2.6% of its workPhysiology: 1 fractional works · 2.4% of its workEpidemiology: 1 fractional works · 2.1% of its workSurgery: 0 fractional works · 1.4% of its workOncology: 0 fractional works · 1.3% of its workPathology and Forensic Medicine: 0 fractional works · 1.1% of its workAnesthesiology and Pain Medicine: 0 fractional works · 1.0% of its workComplementary and alternative medicine: 0 fractional works · 1.0% of its workInfectious Diseases: 0 fractional works · 1.0% of its workHematology: 0 fractional works · 0.9% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.8% of its workInternal Medicine: 0 fractional works · 0.8% of its workImmunology and Allergy: 0 fractional works · 0.5% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.5% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.3% of its workGastroenterology: 0 fractional works · 0.3% of its workPharmacology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workLife Sciences: 10 fractional works · 28.7% of its workNeuroscience: 3 fractional works · 9.5% of its workCellular and Molecular Neuroscience: 3 fractional works · 8.0% of its workDevelopmental Neuroscience: 0 fractional works · 0.7% of its workCognitive Neuroscience: 0 fractional works · 0.3% of its workBiological Psychiatry: 0 fractional works · 0.2% of its workNeurology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workAgricultural and Biological Sciences: 3 fractional works · 8.6% of its workPlant Science: 2 fractional works · 5.7% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 1.5% of its workAnimal Science and Zoology: 0 fractional works · 1.0% of its workFood Science: 0 fractional works · 0.5% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 7.1% of its workMolecular Biology: 1 fractional works · 3.9% of its workGenetics: 1 fractional works · 2.3% of its workCell Biology: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 2.2% of its workPharmaceutical Science: 1 fractional works · 2.2% of its workImmunology and Microbiology: 0 fractional works · 1.1% of its workImmunology: 0 fractional works · 1.1% of its workPhysical Sciences: 7 fractional works · 20.8% of its workEngineering: 3 fractional works · 9.2% of its workBiomedical Engineering: 1 fractional works · 4.0% of its workControl and Systems Engineering: 1 fractional works · 2.1% of its workSafety, Risk, Reliability and Quality: 0 fractional works · 1.5% of its workIndustrial and Manufacturing Engineering: 0 fractional works · 0.5% of its workMechanical Engineering: 0 fractional works · 0.5% of its workElectrical and Electronic Engineering: 0 fractional works · 0.3% of its workAutomotive Engineering: 0 fractional works · 0.2% of its workChemistry: 2 fractional works · 4.4% of its workOrganic Chemistry: 0 fractional works · 1.5% of its workElectrochemistry: 0 fractional works · 1.0% of its workPhysical and Theoretical Chemistry: 0 fractional works · 1.0% of its workSpectroscopy: 0 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.0% of its workComputer Science: 1 fractional works · 3.3% of its workInformation Systems: 1 fractional works · 2.1% of its workArtificial Intelligence: 0 fractional works · 0.9% of its workComputer Science Applications: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.0% of its workMaterials Science: 1 fractional works · 2.2% of its workMaterials Chemistry: 1 fractional works · 2.2% of its workEnvironmental Science: 1 fractional works · 1.7% of its workNature and Landscape Conservation: 0 fractional works · 1.3% of its workEnvironmental Chemistry: 0 fractional works · 0.4% of its workSocial Sciences: 2 fractional works · 7.0% of its workSocial Sciences: 1 fractional works · 4.2% of its workSociology and Political Science: 1 fractional works · 2.5% of its workPolitical Science and International Relations: 0 fractional works · 1.5% of its workTransportation: 0 fractional works · 0.2% of its workPsychology: 0 fractional works · 1.2% of its workClinical Psychology: 0 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.9% of its workEconomics and Econometrics: 0 fractional works · 0.9% of its workBusiness, Management and Accounting: 0 fractional works · 0.5% of its workMarketing: 0 fractional works · 0.5% of its workDecision Sciences: 0 fractional works · 0.2% of its workManagement Science and Operations Research: 0 fractional works · 0.2% of its workALL ITS WORKMarinusPharmaceuticals…34fractional works, all years
Life Sciences29%Physical Sciences21%Health Sciences44%Social Sciences7%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 17 fields, with their numbers
    1. Medicine1543.2%
    2. Nursing00.3%
    1. Neuroscience39.5%
    2. Agricultural and Biological Sciences38.6%
    3. Biochemistry, Genetics and Molecular Biology27.1%
    4. Pharmacology, Toxicology and Pharmaceutics12.2%
    5. Immunology and Microbiology01.1%
    1. Engineering39.2%
    2. Chemistry24.4%
    3. Computer Science13.3%
    4. Materials Science12.2%
    5. Environmental Science11.7%
    1. Social Sciences14.2%
    2. Psychology01.2%
    3. Economics, Econometrics and Finance00.9%
    4. Business, Management and Accounting00.5%
    5. Decision Sciences00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.28× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.00× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 0.33× its world share, 0 worksImmunology and Micro…Neuroscience: 2.65× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 16.91× its world share, 1 worksPharmacology, Toxico…Chemistry: 0.84× its world share, 0 worksChemistryComputer Science: 0.43× its world share, 0 worksComputer ScienceEngineering: 0.44× its world share, 1 worksEngineeringMaterials Science: 0.57× its world share, 0 worksMaterials ScienceMedicine: 3.14× its world share, 8 worksMedicineDecision Sciences: 0.69× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 1.08× its world share, 0 worksEconomics, Econometr…Social Sciences: 0.48× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 16.9×. Every wedge is a field page.

All 13 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics16.91×1 works
  2. Medicine3.14×8 works
  3. Neuroscience2.65×0 works
  4. Economics, Econometrics and Finance1.08×0 works
  5. Biochemistry, Genetics and Molecular Biology1.00×1 works
  6. Chemistry0.84×0 works
  7. Decision Sciences0.69×0 works
  8. Materials Science0.57×0 works
  9. Social Sciences0.48×1 works
  10. Engineering0.44×1 works
  11. Computer Science0.43×0 works
  12. Immunology and Microbiology0.33×0 works
  13. Agricultural and Biological Sciences0.28×0 works

Who are the top researchers at Marinus Pharmaceuticals (United States)?

Ranked on the quality score, Alex A. Aimetti and Salvatore Mascia lead among researchers whose main affiliation is Marinus Pharmaceuticals (United States).

  1. 1 Alex A. Aimetti United States · #582,131 worldwide 3.2k citations · 31 works
  2. 2 Salvatore Mascia United States · #1,008,584 worldwide 1.7k citations · 38 works
All ranked researchers at Marinus Pharmaceuticals (United States)

What are the most cited papers from Marinus Pharmaceuticals (United States)?

The most cited paper from Marinus Pharmaceuticals (United States) is "Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial" (Elia M Pestana Knight et al., 2022), with 158 citations. Next come "Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial" (130) and "Why We Need Continuous Pharmaceutical Manufacturing and How to Make It Happen" (121).

Most cited papers
#PaperReleasedCitations
1 Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial Elia M Pestana Knight et al. · The Lancet Neurology 13 Apr 2022 158
2 Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial Elia Pestana‐Knight, Sam Amin, Nadia Bahi‐Buisson et al. · UCL Discovery (University College London) Open access May 2022 130
3 Why We Need Continuous Pharmaceutical Manufacturing and How to Make It Happen Clive Badman, Charles L. Cooney, Alastair J. Florence et al. · Journal of Pharmaceutical Sciences Open access 2 Aug 2019 121
4 Clinical Evaluation of Ganaxolone in Pediatric and Adolescent Patients with Refractory Epilepsy Vincent A. Pieribone, Julia Y. Tsai, Christine Soufflet et al. · Epilepsia 18 Jul 2007 110
5 Health‐related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials Abiola O. Oladapo, J. Epstein, E. Williams et al. · Haemophilia Review 17 Jul 2015 84
All 77 most cited papers, with filters and sorting

Which keywords describe research at Marinus Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Antiepileptic Drugs, Neurological Disorders, Dendritic Spines, Classification, Synaptic Plasticity, Inflammation, Epilepsy and Neurobiology.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 21 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 21 words, with their numbers
  1. Inflammation4▲ 4.7×6 topics
  2. Antiepileptic Drugs4▲ 106×2 topics
  3. Neurological Disorders3▲ 14×5 topics
  4. Dendritic Spines3▲ 58×2 topics
  5. Classification3▲ 24×2 topics
  6. Synaptic Plasticity3▲ 28×3 topics
  7. Epilepsy3▲ 67×3 topics
  8. Neurobiology3▲ 24×2 topics
  9. Seizures3▲ 108×1 topic
  10. Status Epilepticus3▲ 143×1 topic
  11. GABAergic3▲ 59×1 topic
  12. Neurotransmission3▲ 59×1 topic
  13. Epidemiology2▲ 1.46×8 topics
  14. Cognitive Function2▲ 22×3 topics
  15. Oxidative Stress2▲ 2.3×5 topics
  16. Breast Cancer1▲ 12×3 topics
  17. Climate Change1▲ 1.35×3 topics
  18. Genetic Mutations1▲ 6.7×6 topics
  19. Crystal Engineering1▲ 27×2 topics
  20. CO2 Enrichment1▲ 150×1 topic
  21. Ozone Effects1▲ 150×1 topic

Which research topics does Marinus Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Epilepsy research and treatment, Pharmacological Effects and Toxicity Studies, Cancer-related cognitive impairment studies and Drug Solubulity and Delivery Systems.

Epilepsy research and tr…2Epilepsy research and treatment: 2 fractional worksPharmacological Effects and Toxicity Studies: 1 fractional worksCancer-related cognitive impairment studies: 0 fractional worksDrug Solubulity and Delivery Systems: 0 fractional worksNeuroscience and Neuropharmacology Research: 0 fractional worksAdvanced Breast Cancer Therapies: 0 fractional worksIndustrial and Mining Safety: 0 fractional worksIntellectual Property Rights and Media: 0 fractional worksTraumatic Brain Injury and Neurovascular Disturbances: 0 fractional worksGenetics and Neurodevelopmental Disorders: 0 fractional works
Psychiatry and Mental healthPediatrics, Perinatology and Child HealthPulmonary and Respiratory MedicinePharmaceutical Science5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Epilepsy research and treatment Psychiatry and Mental health 2 works
  2. 2 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 1 works
  3. 3 Cancer-related cognitive impairment studies Pulmonary and Respiratory Medicine 0 works
  4. 4 Drug Solubulity and Delivery Systems Pharmaceutical Science 0 works
  5. 5 Neuroscience and Neuropharmacology Research Cellular and Molecular Neuroscience 0 works
  6. 6 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
  7. 7 Industrial and Mining Safety Safety, Risk, Reliability and Quality 0 works
  8. 8 Intellectual Property Rights and Media Political Science and International Relations 0 works
  9. 9 Traumatic Brain Injury and Neurovascular Disturbances Neurology 0 works
  10. 10 Genetics and Neurodevelopmental Disorders Genetics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available32.6%not open67.4%

World: 40% of research is openly available.

with international co-authors25.1%domestic only74.9%

World: 18% is written across borders.

How has Marinus Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 49% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Marinus Pharmaceuticals (United States) as a percentage of every work published that year, 0.000084% in 2024.

still counting0.000050%0.00010%Marinus Pharmaceuticals (United States)0.0000077% in 202520102020

Fractional works of Marinus Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Radnor

All research institutions in Radnor

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Marinus Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.